Prospera Financial Services’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Prospera Financial Services’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,000	Closed	-$166K	–	1142
2024 Q1	$166K	Hold	10,000	–	–	0.01%	1052
2023 Q4	$135K	Hold	10,000	–	–	﹤0.01%	1016
2023 Q3	$110K	Hold	10,000	–	–	﹤0.01%	973
2023 Q2	$129K	Hold	10,000	–	–	﹤0.01%	971
2023 Q1	$120K	Hold	10,000	–	–	﹤0.01%	928
2022 Q4	$137K	Buy	+10,000	New	+$146K	0.01%	860
2022 Q2	–	Sell	-10,000	Closed	-$180K	–	1782
2022 Q1	$180K	Hold	10,000	–	–	0.01%	912
2021 Q4	$238K	Buy	+10,000	New	+$278K	0.01%	782

Other funds holding CNCR

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SWA

SOA Wealth Advisors New York $595M AUM 25.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Prospera Financial Services's CNCR Position: Q2 2024 in Review

Prospera Financial Services sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2024, closing a stake of 10,000 shares — an estimated $166K sold.

Prospera Financial Services first reported a position in CNCR in Q4 2021 and held it in 8 quarters. The position peaked at $238K in Q4 2021. 13 funds tracked by Wall St. Rank hold CNCR as of Q2 2024.

Prospera Financial Services reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2024 after selling out during the quarter.
Prospera Financial Services sold 10,000 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2024, an estimated $166K.
Prospera Financial Services first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2021 and held it in 8 quarters.
Prospera Financial Services's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $238K in Q4 2021.
13 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2024.

Based on Prospera Financial Services's 13F filing for Q2 2024, filed 13 Aug 2024.